{"url_path":"/sec/brtx/10-q/2026/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-14","source_url":"https://www.sec.gov/Archives/edgar/data/1505497/0001493152-26-023126-index.html","accession_number":"0001493152-26-023126","cik":"0001505497","ticker":"BRTX","issuer_name":"BioRestorative Therapies, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1505497/0001493152-26-023126-index.html","primary_entity_key":"0001505497","primary_entity_name":"BioRestorative Therapies, Inc."},"word_count":927,"has_tables":true,"body_markdown":"false\n--12-31\nQ1\n0001505497\n\n0001505497\n\n2026-01-01\n2026-03-31\n\n0001505497\n\n2026-05-14\n\n0001505497\n\n2026-03-31\n\n0001505497\n\n2025-12-31\n\n0001505497\n\nBRTX:SeriesBConvertiblePreferredStockMember\n\n2026-03-31\n\n0001505497\n\nBRTX:SeriesBConvertiblePreferredStockMember\n\n2025-12-31\n\n0001505497\n\n2025-01-01\n2025-03-31\n\n0001505497\n\nus-gaap:PreferredStockMember\nBRTX:SeriesBConvertiblePreferredStockMember\n\n2025-12-31\n\n0001505497\n\nus-gaap:CommonStockMember\n\n2025-12-31\n\n0001505497\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2025-12-31\n\n0001505497\n\nus-gaap:RetainedEarningsMember\n\n2025-12-31\n\n0001505497\n\nus-gaap:PreferredStockMember\nBRTX:SeriesBConvertiblePreferredStockMember\n\n2024-12-31\n\n0001505497\n\nus-gaap:CommonStockMember\n\n2024-12-31\n\n0001505497\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2024-12-31\n\n0001505497\n\nus-gaap:RetainedEarningsMember\n\n2024-12-31\n\n0001505497\n\n2024-12-31\n\n0001505497\n\nus-gaap:PreferredStockMember\nBRTX:SeriesBConvertiblePreferredStockMember\n\n2026-01-01\n2026-03-31\n\n0001505497\n\nus-gaap:CommonStockMember\n\n2026-01-01\n2026-03-31\n\n0001505497\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2026-01-01\n2026-03-31\n\n0001505497\n\nus-gaap:RetainedEarningsMember\n\n2026-01-01\n2026-03-31\n\n0001505497\n\nus-gaap:PreferredStockMember\nBRTX:SeriesBConvertiblePreferredStockMember\n\n2025-01-01\n2025-03-31\n\n0001505497\n\nus-gaap:CommonStockMember\n\n2025-01-01\n2025-03-31\n\n0001505497\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2025-01-01\n2025-03-31\n\n0001505497\n\nus-gaap:RetainedEarningsMember\n\n2025-01-01\n2025-03-31\n\n0001505497\n\nus-gaap:PreferredStockMember\nBRTX:SeriesBConvertiblePreferredStockMember\n\n2026-03-31\n\n0001505497\n\nus-gaap:CommonStockMember\n\n2026-03-31\n\n0001505497\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2026-03-31\n\n0001505497\n\nus-gaap:RetainedEarningsMember\n\n2026-03-31\n\n0001505497\n\nus-gaap:PreferredStockMember\nBRTX:SeriesBConvertiblePreferredStockMember\n\n2025-03-31\n\n0001505497\n\nus-gaap:CommonStockMember\n\n2025-03-31\n\n0001505497\n\nus-gaap:AdditionalPaidInCapitalMember\n\n2025-03-31\n\n0001505497\n\nus-gaap:RetainedEarningsMember\n\n2025-03-31\n\n0001505497\n\n2025-03-31\n\n0001505497\n\nBRTX:RodmanOfferingMember\n\n2026-01-01\n2026-03-31\n\n0001505497\n\nBRTX:ATMSalesMember\n\n2025-01-01\n2025-03-31\n\n0001505497\n\nBRTX:PreFundedWarrantsMember\n\n2026-03-31\n\n0001505497\n\n2026-03-26\n\n0001505497\n\nBRTX:ResearchAndDevelopmentExpenses\n\nus-gaap:EmployeeStockOptionMember\n\n2025-01-01\n2025-03-31\n\n0001505497\n\nus-gaap:USTreasuryNotesSecuritiesMember\n\n2026-03-31\n\n0001505497\n\nus-gaap:USTreasuryNotesSecuritiesMember\n\n2026-01-01\n2026-03-31\n\n0001505497\n\nBRTX:AccruedInterestMember\n\n2026-03-31\n\n0001505497\n\nBRTX:AccruedInterestMember\n\n2026-01-01\n2026-03-31\n\n0001505497\n\nus-gaap:USTreasuryNotesSecuritiesMember\n\n2025-12-31\n\n0001505497\n\nus-gaap:USTreasuryNotesSecuritiesMember\n\n2025-01-01\n2025-12-31\n\n0001505497\n\nBRTX:AccruedInterestMember\n\n2025-12-31\n\n0001505497\n\nBRTX:AccruedInterestMember\n\n2025-01-01\n2025-12-31\n\n0001505497\n\n2025-01-01\n2025-12-31\n\n0001505497\n\nus-gaap:ProductMember\n\n2026-01-01\n2026-03-31\n\n0001505497\n\nus-gaap:ProductMember\n\n2025-01-01\n2025-03-31\n\n0001505497\n\nus-gaap:RoyaltyMember\n\n2026-01-01\n2026-03-31\n\n0001505497\n\nus-gaap:RoyaltyMember\n\n2025-01-01\n2025-03-31\n\n0001505497\n\nus-gaap:EmployeeStockOptionMember\n\n2026-01-01\n2026-03-31\n\n0001505497\n\nus-gaap:EmployeeStockOptionMember\n\n2025-01-01\n2025-03-31\n\n0001505497\n\nus-gaap:WarrantMember\n\n2026-01-01\n2026-03-31\n\n0001505497\n\nus-gaap:WarrantMember\n\n2025-01-01\n2025-03-31\n\n0001505497\n\nus-gaap:ConvertiblePreferredStockMember\n\n2026-01-01\n2026-03-31\n\n0001505497\n\nus-gaap:ConvertiblePreferredStockMember\n\n2025-01-01\n2025-03-31\n\n0001505497\n\nus-gaap:CommonStockMember\n\n2024-02-06\n\n0001505497\n\nus-gaap:CommonStockMember\nBRTX:AuctusFundLLCMember\n\n2025-12-31\n\n0001505497\n\nus-gaap:CommonStockMember\n\n2026-02-10\n2026-02-10\n\n0001505497\n\nus-gaap:CommonStockMember\n\n2026-02-13\n2026-02-13\n\n0001505497\n\nus-gaap:CommonStockMember\nus-gaap:PrivatePlacementMember\n\n2024-02-06\n2024-02-06\n\n0001505497\n\nus-gaap:CommonStockMember\nus-gaap:PrivatePlacementMember\n\n2024-02-06\n\n0001505497\n\n2026-01-01\n2026-02-24\n\n0001505497\n\nus-gaap:EmployeeStockOptionMember\nus-gaap:ShareBasedPaymentArrangementEmployeeMember\n\n2025-02-14\n2025-02-14\n\n0001505497\n\nus-gaap:CommonStockMember\nBRTX:ATMProgramMember\n\n2025-02-01\n2025-02-28\n\n0001505497\n\nus-gaap:CommonStockMember\nBRTX:ATMProgramMember\n\n2025-02-28\n\n0001505497\n\nus-gaap:CommonStockMember\nBRTX:ATMProgramMember\n\n2025-01-01\n2025-03-31\n\n0001505497\n\nBRTX:CommonUnitsMember\n\n2026-02-13\n2026-02-13\n\n0001505497\n\nBRTX:CommonStockWarrantsMember\n\n2026-02-13\n\n0001505497\n\nus-gaap:CommonStockMember\n\n2026-02-13\n\n0001505497\n\nBRTX:PreFundedUnitsMember\n\n2026-02-13\n\n0001505497\n\nBRTX:PreFundedWarrantsMember\n\n2026-02-13\n\n0001505497\n\nus-gaap:WarrantMember\n\n2026-02-13\n\n0001505497\n\nBRTX:RodmanOfferingMember\n\n2026-02-13\n\n0001505497\n\nBRTX:PreFundedWarrantsMember\n\n2026-03-13\n\n0001505497\n\n2026-02-13\n2026-02-13\n\n0001505497\n\nBRTX:PlacementAgencyAgreementMember\n\n2026-02-11\n2026-02-11\n\n0001505497\n\n2026-02-11\n\n0001505497\n\nBRTX:PlacementAgencyAgreementMember\n\n2026-02-11\n\n0001505497\n\nus-gaap:SeriesBPreferredStockMember\n\n2026-02-24\n2026-02-24\n\n0001505497\n\nus-gaap:CommonStockMember\n\n2026-02-24\n2026-02-24\n\n0001505497\n\nBRTX:SeriesBConvertiblePreferredStockMember\nBRTX:AuctusFundLLCMember\n\n2026-03-31\n\n0001505497\n\nBRTX:BoardOfDirectorsMember\nsrt:MinimumMember\n\n2025-06-16\n2025-06-16\n\n0001505497\n\nBRTX:AuctusFundLLCMember\n\n2025-01-01\n2025-03-31\n\n0001505497\n\nBRTX:AuctusFundLLCMember\n\n2026-01-01\n2026-03-31\n\n0001505497\n\nBRTX:PreFundedWarrantsMember\n\n2026-01-01\n2026-03-31\n\n0001505497\n\nus-gaap:SeriesBPreferredStockMember\n\n2026-01-01\n2026-03-31\n\n0001505497\n\nus-gaap:WarrantMember\n\n2026-01-01\n2026-03-31\n\n0001505497\n\nus-gaap:MeasurementInputRiskFreeInterestRateMember\n\n2024-02-13\n2024-02-13\n\n0001505497\n\nus-gaap:MeasurementInputExpectedTermMember\n\n2024-02-13\n2024-02-13\n\n0001505497\n\nus-gaap:MeasurementInputPriceVolatilityMember\n\n2024-02-13\n2024-02-13\n\n0001505497\n\nus-gaap:MeasurementInputExpectedDividendRateMember\n\n2024-02-13\n2024-02-13\n\n0001505497\n\nus-gaap:MeasurementInputRiskFreeInterestRateMember\nBRTX:ExistingWarrantsAndNewWarrantsMember\nus-gaap:FairValueInputsLevel3Member\n\n2026-02-24\n2026-02-24\n\n0001505497\n\nus-gaap:MeasurementInputExpectedTermMember\nsrt:MinimumMember\nBRTX:ExistingWarrantsAndNewWarrantsMember\nus-gaap:FairValueInputsLevel3Member\n\n2026-02-24\n2026-02-24\n\n0001505497\n\nus-gaap:MeasurementInputExpectedTermMember\nsrt:MaximumMember\nBRTX:ExistingWarrantsAndNewWarrantsMember\nus-gaap:FairValueInputsLevel3Member\n\n2026-02-24\n2026-02-24\n\n0001505497\n\nus-gaap:MeasurementInputPriceVolatilityMember\nBRTX:ExistingWarrantsAndNewWarrantsMember\nsrt:MinimumMember\nus-gaap:FairValueInputsLevel3Member\n\n2026-02-24\n2026-02-24\n\n0001505497\n\nus-gaap:MeasurementInputPriceVolatilityMember\nBRTX:ExistingWarrantsAndNewWarrantsMember\nsrt:MaximumMember\nus-gaap:FairValueInputsLevel3Member\n\n2026-02-24\n2026-02-24\n\n0001505497\n\nus-gaap:MeasurementInputExpectedDividendRateMember\nBRTX:ExistingWarrantsAndNewWarrantsMember\nus-gaap:FairValueInputsLevel3Member\n\n2026-02-24\n2026-02-24\n\n0001505497\n\nus-gaap:WarrantMember\n\n2025-12-31\n\n0001505497\n\nus-gaap:WarrantMember\n\n2026-01-01\n2026-03-31\n\n0001505497\n\nus-gaap:WarrantMember\n\n2026-03-31\n\n0001505497\n\nsrt:MinimumMember\n\n2025-01-01\n2025-03-31\n\n0001505497\n\nsrt:MaximumMember\n\n2025-01-01\n2025-03-31\n\n0001505497\n\nBRTX:ResearchAndDevelopmentExpenses\n\nus-gaap:EmployeeStockOptionMember\n\n2026-01-01\n2026-03-31\n\n0001505497\n\nBRTX:GeneralAndAdministrativeExpenses\n\nus-gaap:EmployeeStockOptionMember\n\n2026-01-01\n2026-03-31\n\n0001505497\n\nBRTX:GeneralAndAdministrativeExpenses\n\nus-gaap:EmployeeStockOptionMember\n\n2025-01-01\n2025-03-31\n\n0001505497\n\nBRTX:ExistingWarrantsAndNewWarrantsMember\nBRTX:BlackScholesOptionMember\n\n2026-02-24\n2026-02-24\n\n0001505497\n\nBRTX:ExistingWarrantsAndNewWarrantsMember\n\n2026-01-01\n2026-03-31\n\n0001505497\n\nus-gaap:FairValueInputsLevel1Member\n\n2026-03-31\n\n0001505497\n\nus-gaap:FairValueInputsLevel2Member\n\n2026-03-31\n\n0001505497\n\nus-gaap:FairValueInputsLevel3Member\n\n2026-03-31\n\n0001505497\n\nus-gaap:FairValueInputsLevel1Member\n\n2025-12-31\n\n0001505497\n\nus-gaap:FairValueInputsLevel2Member\n\n2025-12-31\n\n0001505497\n\nus-gaap:FairValueInputsLevel3Member\n\n2025-12-31\n\n0001505497\n\nBRTX:BoardOfDirectorsMember\nus-gaap:SubsequentEventMember\n\n2026-04-02\n\niso4217:USD\n\nxbrli:shares\n\niso4217:USD\n\nxbrli:shares\n\nxbrli:pure\n\nBRTX:Segment\n\nutr:sqft\n\n \n\n \n\n \n\n**UNITED\nSTATES**\n\n**SECURITIES\nAND EXCHANGE COMMISSION**\n\n**Washington,\nD.C. 20549**\n\n \n\n**FORM\n10-Q**\n\n \n\n☒\n**QUARTERLY\nREPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**\n\n \n\n**For\nthe Quarterly Period Ended March 31, 2026**\n\n \n\n**or**\n\n \n\n☐\n**TRANSITION\nREPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**\n\n \n\n**For\nthe Transition Period from _________ to _________**\n\n \n\n**Commission\nfile number: 001-37603**\n\n \n\n**BIORESTORATIVE\nTHERAPIES, INC.**\n\n(Exact\nname of registrant as specified in its charter)\n\n \n\n**Nevada**\n \n**30-1341024**\n\n(State\nor other Jurisdiction of\n\nIncorporation\nor Organization)\n\n \n\n(I.R.S.\nEmployer\n\nIdentification\nNo.)\n\n \n\n**40\nMarcus Drive, Melville, New York**\n \n**11747**\n\n(Address\nof Principal Executive Offices)\n \n(Zip\nCode)\n\n \n\n**(631)\n760-8100**\n\n(Registrant’s\ntelephone number, including area code)\n\n \n\nSecurities\nregistered pursuant to Section 12(b) of the Act:\n\n \n\n**Title\nof each class**\n \n**Trading\nsymbol(s)**\n \n**Name\nof exchange on which registered**\n\nCommon\nStock, $0.0001 par value\n \nBRTX\n \nNasdaq\nCapital Market\n\n \n\nIndicate\nby check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange\nAct of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)\nhas been subject to such filing requirements for the past 90 days. Yes ☒ No ☐\n\n \n\nIndicate\nby check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule\n405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant\nwas required to submit such files). Yes ☒ No ☐\n\n \n\nIndicate\nby check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting\ncompany, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,”\n“smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.\n\n \n\nLarge\naccelerated filer\n☐\nAccelerated\nfiler\n☐\n\n \n \n \n \n\nNon-accelerated\nfiler\n☒\nSmaller\nreporting company\n☒\n\n \n \n \n \n\n \n \nEmerging\ngrowth company\n☐\n\n \n\nIf\nan emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying\nwith any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act: ☐\n\n \n\nIndicate\nby check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒\n\n \n\nIndicate\nby checkmark whether the registrant has filed all documents and reports required to be filed by Sections 12, 13 or 15(d) of the Securities\nExchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court. Yes ☒ No ☐\n\n \n\nAs\nof May 14, 2026 there were 25,478,170 shares of the registrant’s Common Stock outstanding.\n\n \n\n \n\n \n\n \n\n \n\n** **\n\n**BIORESTORATIVE\nTHERAPIES, INC.**\n\n \n\n**FORM\n10-Q**\n\n \n\n**FOR\nTHE THREE MONTHS ENDED MARCH 31, 2026 AND 2025**\n\n \n\n**TABLE\nOF CONTENTS**\n\n \n\n \n \nPage\n\n \n \n \n\n**PART I - FINANCIAL INFORMATION**\n3"}